The Avantgarde Carbostent in Patients Scheduled for Undelayable Noncardiac Surgery. (19th February 2012)

• Record Type: Journal Article
• Authors: Briguori, Carlo; Visconti, Gabriella; De Micco, Francesca; Focaccio, Amelia
• Other Names: Chieffo Alaide Academic Editor.
• Is Part Of: Thrombosis. Volume 2012(2012)
• Publication Date: 2012-02-19
• Subjects: Thrombosis -- Periodicals; Thrombosis; Thrombosis; Electronic journals; Periodical; Electronic journals; Periodicals; 616.135
• DOI: 10.1155/2012/372371
• Languages: English
• ISSNs: 2090-1488

Abstract

Abstract : Background . Treatment of patients who need coronary revascularization before undelayable non-cardiac surgery is challenging. Methods . We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the Avantgarde TM Carbostent (CID, Italy) in patients undergoing PCI before undelayable non-cardiac surgery. The Multiplate analyzer point-of-care was used to assess residual platelet reactivity. One major cardiac events (MACE, defined as death, myocardial infarction, and stent thrombosis and major bleeding) were assessed. Results . 42 consecutive patients were analyzed. Total stent length ≥25 mm was observed in 16 (37%) patients. Multivessel stenting was performed in 11 (31.5%) patients. Clopidogrel was interrupted 5 days before surgery in 35 patients, whereas it was stopped the day of the surgery in 7 patients. Surgery was performed after 27 ± 9 (7–42) days from PCI. MACE occurred in one patient (2.4%; 95% confidence interval: 0.01–13%), who had fatal acute myocardial infarction 3 days after abdominal aortic aneurysm surgery and 12 days after stent implantation. No case of major bleeding in the postoperative phase was observed. Conclusions . The present pilot study suggests that, although at least 10–14 days of dual antiplatelet therapy remain mandatory, the Avantgarde TM stent seems to have a role in patients requiring undelayable surgery.